Outlook Therapeutics, Inc. financial data

Symbol
OTLK on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
111 S. Wood Avenue, Unit #100, Iselin, NJ
State of incorporation
DE
Fiscal year end
September 30
Former names
Oncobiologics, Inc. (to 11/13/2018)
Latest financial report
10-Q - Q4 2024 - Feb 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 78.2 % -1.31%
Debt-to-equity -145 % +73.8%
Return On Equity 54.9 % -91%
Return On Assets -123 % +8.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24.9M shares -90.4%
Common Stock, Shares, Outstanding 24.9M shares -90.4%
Entity Public Float 180M USD +0.5%
Common Stock, Value, Issued 249K USD -90.4%
Weighted Average Number of Shares Outstanding, Basic 24.2M shares +86.2%
Weighted Average Number of Shares Outstanding, Diluted 24.2M shares +86.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 46.9M USD +122%
General and Administrative Expense 36.1M USD +35.5%
Operating Income (Loss) -83M USD -73.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 44.4M USD
Income Tax Expense (Benefit) 2.8K USD 0%
Net Income (Loss) Attributable to Parent -46.8M USD +9.1%
Earnings Per Share, Basic -2.48 USD/shares +54.9%
Earnings Per Share, Diluted -2.48 USD/shares +54.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.7M USD -44.9%
Inventory, Net 3.11M USD
Assets, Current 15.7M USD -23.2%
Operating Lease, Right-of-Use Asset 263K USD +1657%
Other Assets, Noncurrent 416K USD -14.1%
Assets 17M USD -21.6%
Accounts Payable, Current 12.2M USD +250%
Employee-related Liabilities, Current 683K USD -38.6%
Accrued Liabilities, Current 3.39M USD -17%
Liabilities, Current 48.2M USD +4.94%
Operating Lease, Liability, Noncurrent 233K USD
Liabilities 67.3M USD +46.2%
Retained Earnings (Accumulated Deficit) -526M USD -9.77%
Stockholders' Equity Attributable to Parent -50.3M USD -107%
Liabilities and Equity 17M USD -21.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11M USD +15.8%
Net Cash Provided by (Used in) Financing Activities 1.74M USD
Common Stock, Shares Authorized 60M shares -85.9%
Common Stock, Shares, Issued 24.9M shares -90.4%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.22M USD +29.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.7M USD -44.9%
Deferred Tax Assets, Valuation Allowance 139M USD +15.9%
Deferred Tax Assets, Gross 139M USD +16%
Operating Lease, Liability 286K USD
Lessee, Operating Lease, Liability, to be Paid 354K USD
Operating Lease, Liability, Current 52.6K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 81.8K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 80K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +26.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 67.9K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 83.7K USD
Deferred Tax Assets, Operating Loss Carryforwards 103M USD +10.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares +37%
Unrecognized Tax Benefits 1.86M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 49.4K USD
Operating Lease, Payments 19.3K USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 77.2K USD +949%
Share-based Payment Arrangement, Expense 7.78M USD +43.4%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%